Corbenic Partners’s Unity Biotechnology UBX Stock Holding History

Corbenic Partners’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-196	Closed	-$2K	–	242
2022 Q1	$2K	Hold	196	–	–	﹤0.01%	213
2021 Q4	$3K	Hold	196	–	–	﹤0.01%	244
2021 Q3	$6K	Hold	196	–	–	﹤0.01%	198
2021 Q2	$9K	Hold	196	–	–	﹤0.01%	187
2021 Q1	$12K	Hold	196	–	–	﹤0.01%	166
2020 Q4	$10K	Buy	+196	New	+$9.45K	﹤0.01%	129

Other funds holding UBX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corbenic Partners's UBX Position: Q2 2022 in Review

Corbenic Partners sold out of Unity Biotechnology (UBX) in Q2 2022, closing a stake of 196 shares — an estimated $2K sold.

Corbenic Partners first reported a position in UBX in Q4 2020 and held it in 6 quarters. The position peaked at $12K in Q1 2021. 65 funds tracked by Wall St. Rank hold UBX as of Q2 2022.

Corbenic Partners reported no remaining Unity Biotechnology position as of Q2 2022 after selling out during the quarter.
Corbenic Partners sold 196 Unity Biotechnology shares in Q2 2022, an estimated $2K.
Corbenic Partners first reported a position in Unity Biotechnology in Q4 2020 and held it in 6 quarters.
Corbenic Partners's Unity Biotechnology position peaked at $12K in Q1 2021.
65 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.